Oxford Biomedica Regulatory News (OXB)

OXFORD BIOMEDICA PLC

MANAGEMENT AND BOARD CHANGES

Oxford BioMedica Appoints Alex Lewis as Director of Corporate Activities and Strategy

Oxford, UK - 24 May 2011: Oxford BioMedica (LSE: OXB), a leading gene therapy company, today announces that Dr Alex Lewis has been appointed as Director of Corporate Activities and Strategy and a member of the senior management team with immediate effect. As a result, he will step down from the Board of Oxford BioMedica.

Alex is an experienced consultant to the pharmaceutical and biotech industry with a background of over 24 years in medical research and drug development. Alex was appointed to Oxford BioMedica's Board in April 2008 and was also Director of Transactions and Due Diligence at The Datamonitor Group until June 2009 when he became Director of Lewis Healthcare Consultants. Prior to this, he was Head of the Partnering and Due Diligence practice of Wood Mackenzie research consultants. Alex has also been involved in the provision of expert reports and technical advice for the initial public offerings and fundraising activities for biotech companies based in the US and Europe.

John Dawson, Chief Executive Officer of Oxford BioMedica, said: "Alex is an expert addition to the senior management team as we continue to build Oxford BioMedica as a successful biopharmaceutical company founded on the development and commercialisation of products derived from innovative technology platforms. Alex's knowledge and advice will also be instrumental in evaluating other value-enhancing opportunities to grow the business."

In place of Dr Alex Lewis, Dr Paul Blake will become Chairman of Oxford BioMedica's remuneration committee and Dr Andrew Heath, Senior Independent Director and Deputy Chairman of Oxford BioMedica, will join the Company's remuneration committee.

-Ends-

Notes to editors

1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Further information is available at www.oxfordbiomedica.co.uk.